Brief: Pacira Biosciences Q2 Cash & Investments USD 404.2 Million
30/07/2024 21:00
Jul 30 (Reuters) - Pacira Biosciences Q2 adjusted EBITDA USD 62.1 million vs. IBES estimate USD 52.8 million. * Q2 adjusted net income USD 44.2 million vs. IBES estimate USD 35.3 million * Q2 net income USD 18.9 million * Q2 revenue USD 178 million vs. IBES estimate USD 172.5 million
Recent news on Pacira Biosciences
See all newsBrief: Pacira Biosciences Inc - Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "For" All Of Pacira's Director Nominees
Brief: Pacira Biosciences Urges Stockholders To Vote "For" Election Of Pacira's Nominees On Blue Proxy Card
Brief: Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy
Brief: Doma Perpetual Capital Management Calls For Removal Of Pacira CEO And Strategic Sale
Brief: Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees